Ovarian Cancer — Year in Review Series on Relevant New Datasets and Advances
Oncology Today with Dr Neil Love
00:00
Reluzoltog (DXD) efficacy and tolerability
Kathleen shares phase 1 experience: strong responses, emetogenicity management, and ILD vigilance with relutatatog.
Play episode from 20:25
Transcript
